Immunogenicity and clinical activity of Tipapkinogen sovacivec (TG4001), an HPV-16 cancer vaccine: a randomized phase 2 study in recurrent or metastatic (R/M) anogenital cancersC. Le Tourneau, et al.ESMO 2023Abstract available on the ESMO website – Download the abstract – Download the poster